Anglia Ruskin University and Arctic Bioscience are researching herring roe omega-3 to uncover its benefits for exercise ...

A phase 2 trial shows that olpasiran, an RNA-based therapy, reduces lipoprotein(a) [Lp(a)] levels by more than 95% in ...

Pharmaceutical Lipids Market to Reach USD 9,036.5 Million by 2035, Rising demand for lipid-based drug delivery fuels market growth, enhancing solubil ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

Insulin-like growth factor (IGF) 1 is a member of a family that is involved in growth, development, cell differentiation, and metabolism. IGF1, IGF2 and insulin act primarily through tyrosine ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according ...

The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

M etabolic-Associated Fatty Liver Disease or MAFLD is increasingly common in the Philippines, especially among those in their ...

Anglia Ruskin University (ARU) in Cambridge, England, has teamed up with Norwegian biotech company Arctic Bioscience to conduct the largest research project to date on the health benefits of omega-3 ...

Thyroid hormones help regulate the body's metabolic rate, which is a measure of how efficient it is at using energy. When the thyroid isn’t producing enough of certain hormones, metabolism slows down; ...